The makers of medicine ‘bapineuzumab’ for Alzheimer disease suffered a loss in Wyeth’s stock market and their shares were closed down nearly 12 percent, at $39.74. Similarly, shares in Elan, an Irish company, were down nearly 42 in New York trading, ending at $19.63.

 

Earlier, the question of efficacy of the medicine was raised, and there were also huge variations in its effectiveness among patients and no clear signs of a better response according to the dose given. Now, Elan and Wyeth have begun final phase 3clinical trials of bapineuzumab.

 

However, the Elan and Wyeth do not seem to be bothered about share market performance of the medicine, and have started preparing the last stage of medicine before seeking federal approval for the drug. The medicine can re-enter into market in next couple of years.